News

The Dose Podcast- Episode 4 "PAN-TB and Novel Regimen Development"

 

Episode 4 of the WGND's podcast series, The Dose, is now available for streaming. In this episode join our moderator, Shobha Shukla, as she speaks with TB regimen development experts Dr. Debra Hanna and Dr. Robert Bates on the topic of the PAN-TB collaboration and novel regimen development. The PAN-TB collaboration of philanthropic, non-profit, and private sector organizations supported by the Bill & Melinda Gates Foundation strives to accelerate the development of shorter, safer, and affordable TB therapy with minimal existing drug resistance. 

The Working Group on New TB Drugs (WGND)’s podcast series The Dose explores pressing issues and emerging solutions related to research and development of new tuberculosis drugs. The podcast series provides the opportunity to hear from key experts in the TB drug field and disseminate information using a new and innovative platform. The WGND strives to cover the most pressing issues facing TB drug development and the podcast series has the potential to reach a broad audience. The WGND hopes to use the podcast platform to bring together drug developers, researchers in the TB R&D field, TB patients, and donors to discuss, prioritize, and develop strategies to help meet the most pressing drug research and development needs related to tuberculosis.

Episode 4 "PAN-TB and TB Regimen Development" 

Moderator:
Shobha Shukla
Citizen News Service
India

PAN-TB Leader
Debra Hanna
Senior Program Officer, TB Drugs, BMGF
USA

PAN-TB Partner
Robert Bates
Director, Head of Tuberculosis Discovery, GSK
Spain

To listen, click play on the vimeo box at the top of the page or visit https://vimeo.com/534117379. The views expressed in this podcast are those of the individual panelists and do not necessarily represent their organizations’ opinions.

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...